MENU
+Compare
ADMA
Stock ticker: NASDAQ
AS OF
Apr 1, 04:59 PM (EDT)
Price
$19.40
Change
-$0.44 (-2.22%)
Capitalization
4.61B

ADMA ADMA Biologics Forecast, Technical & Fundamental Analysis

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases... Show more

Industry: #Biotechnology
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ADMA with price predictions
Mar 31, 2025

ADMA in +3.41% Uptrend, advancing for three consecutive days on March 24, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ADMA advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on March 04, 2025. You may want to consider a long position or call options on ADMA as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ADMA just turned positive on February 28, 2025. Looking at past instances where ADMA's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

ADMA moved above its 50-day moving average on March 11, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ADMA crossed bullishly above the 50-day moving average on March 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ADMA moved out of overbought territory on March 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ADMA broke above its upper Bollinger Band on March 19, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ADMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.228) is normal, around the industry mean (13.677). P/E Ratio (23.975) is within average values for comparable stocks, (64.969). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.870). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (11.086) is also within normal values, averaging (255.565).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ADMA is expected to report earnings to fall 68.11% to 14 cents per share on May 07

ADMA Biologics ADMA Stock Earnings Reports
Q1'25
Est.
$0.15
Q4'24
Beat
by $0.31
Q3'24
Beat
by $0.02
Q2'24
Beat
by $0.05
Q1'24
Beat
by $0.03
The last earnings report on March 03 showed earnings per share of 46 cents, beating the estimate of 15 cents. With 2.22M shares outstanding, the current market capitalization sits at 4.61B.
A.I. Advisor
published General Information

General Information

an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
465 State Route 17
Phone
+1 201 478-5552
Employees
624
Web
https://www.admabiologics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GAA29.120.25
+0.86%
Cambria Global Asset Allocation ETF
HTRB33.860.07
+0.21%
Hartford Total Return Bond ETF
FSLD50.200.04
+0.07%
Fidelity Sustainable Low Dur Bd ETF
DFEN30.70-0.09
-0.29%
Direxion Dly Aerospace&Def Bl 3X ShsETF
CCD21.29-0.15
-0.70%
Calamos Dynamic Convertible & Income Fund

ADMA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with ATRA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then ATRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
-2.07%
ATRA - ADMA
44%
Loosely correlated
-9.04%
TARS - ADMA
40%
Loosely correlated
-0.72%
RCUS - ADMA
37%
Loosely correlated
-3.92%
LOGC - ADMA
36%
Loosely correlated
+0.43%
ACLX - ADMA
36%
Loosely correlated
-3.47%
More